Amylyx Pharmaceuticals
AMLX
119 hedge funds and large institutions have $82.9M invested in Amylyx Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 29 increasing their positions, 44 reducing their positions, and 53 closing their positions.
8.9% less ownership
Funds ownership: 73.06% → 64.16% (-8.9%)
17% less funds holding
Funds holding: 143 → 119 (-24)
34% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 44
40% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 53
41% less capital invested
Capital invested by funds: $141M → $82.9M (-$58.5M)
86% less call options, than puts
Call options by funds: $546K | Put options by funds: $4.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$6.25M |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
+$3.69M |
| 3 |
6CM
683 Capital Management
New York
|
+$2.91M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.35M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.27M |
| 2 |
State Street
Boston,
Massachusetts
|
-$3.69M |
| 3 |
BlackRock
New York
|
-$3.5M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.87M |
| 5 |
Morgan Stanley
New York
|
-$2.22M |
AMLX Hedge Fund Activity: Q2 2024 in Review
119 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2024, worth a combined $82.9M — down 41% from $141M a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of AMLX and 32 opened new positions — a net loss of 21 holders — while 44 trimmed existing stakes and 29 added.
The largest buyer was AQR Capital Management, adding an estimated $6.25M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.27M sold.
- 119 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2024, down from 143 in Q1 2024.
- Funds reported $82.9M of Amylyx Pharmaceuticals stock for Q2 2024, down 41% quarter-over-quarter.
- 32 funds opened new Amylyx Pharmaceuticals positions in Q2 2024 and 53 closed out, a net change of -21 holders.
- The largest Amylyx Pharmaceuticals buyer in Q2 2024 was AQR Capital Management, an estimated $6.25M added.
- The largest Amylyx Pharmaceuticals seller in Q2 2024 was Franklin Resources, an estimated $5.27M sold.
Based on aggregated 13F filings for Q2 2024.